Depression and Anxiety in Parkinson's Disease: Prevalence and Associated Risk Factors

被引:0
作者
Alis, Ceren [1 ]
Demirelli, Derya Selcuk [1 ]
Ay, Elvin [2 ]
Genc, Gencer [1 ]
机构
[1] Univ Hlth Sci Turkiye, Sisli Hamidiye Etfal Training & Res Hosp, Dept Neurol, Istanbul, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Dept Neurol, Fac Med, Istanbul, Turkiye
来源
MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL | 2025年 / 59卷 / 02期
关键词
Anxiety; depression; mental health; Parkinson's disease; psychiatric comorbidity; quality of life; RESTLESS LEGS SYNDROME; DISORDERS; SYMPTOMS; FREQUENCY;
D O I
10.14744/SEMB.2025.90767
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Parkinson's disease (PD) is a neurodegenerative disorder with both motor and non-motor symptoms, including depression and anxiety, which significantly impact patients' quality of life. The predictors of these psychiatric symptoms remain incompletely understood. This study aims to evaluate the prevalence and potential predictors of depression and anxiety in PD. Methods: A prospective study was conducted on 99 idiopathic PD patients. Depression and anxiety were assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) scale. A range of clinical and demographic variables, including motor symptoms, sleep disturbances, and quality of life, were analyzed using regression models. Results: Of the patients, 57.5% had depression, 48.4% had anxiety, and 36.3% had both. Significant predictors of depression included the use of apomorphine, which was associated with lower PHQ-9 scores (p=0.031), and the presence of restless legs syndrome (RLS), which was linked to higher depression scores (p=0.037). For anxiety, younger age was a significant predictor (p=0.007). Both depression and anxiety scores correlated with lower quality of life (p<0.001 for both). Conclusion: This study highlights the high prevalence of depression and anxiety in PD, with significant predictors including RLS for depression and younger age for anxiety. Apomorphine use appears protective against depression. Both depression and anxiety disrupt quality of life. These findings underscore the importance of routine psychiatric screening and comprehensive management of depression and anxiety in PD, aiming to improve patient outcomes.
引用
收藏
页码:200 / 205
页数:6
相关论文
共 27 条
[21]   Pathology of behavior in PD: What is known and what is not? [J].
Martens, Kaylena A. Ehgoetz ;
Lewis, Simon J. G. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 374 :9-16
[22]   Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease [J].
Mueller, Christoph ;
Rajkumar, Anto P. ;
Wan, Yi Min ;
Velayudhan, Latha ;
ffytche, Dominic ;
Chaudhuri, Kallol Ray ;
Aarsland, Dag .
CNS DRUGS, 2018, 32 (07) :621-635
[23]   A systematic review of prevalence studies of depression in Parkinson's disease [J].
Reijnders, Jennifer S. A. M. ;
Ehrt, Uwe ;
Weber, Wim E. J. ;
Aarsland, Dag ;
Leentjens, Albert F. G. .
MOVEMENT DISORDERS, 2008, 23 (02) :183-189
[24]  
Riedel O, 2012, PARKINSONISM RELAT D, V18, P598, DOI [10.1016/j.parkreldis.2011.11.007, 10.1016/S1353-8020(11)70028-1]
[25]   The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naive Parkinson's disease [J].
Rutten, Sonja ;
Vriend, Chris ;
van der Werf, Ysbrand D. ;
Berendse, Henk W. ;
Weintraub, Daniel ;
van den Heuvel, Odile A. .
PARKINSONISM & RELATED DISORDERS, 2017, 39 :31-36
[26]   A brief measure for assessing generalized anxiety disorder -: The GAD-7 [J].
Spitzer, Robert L. ;
Kroenke, Kurt ;
Williams, Janet B. W. ;
Loewe, Bernd .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (10) :1092-1097
[27]  
WILLIAMS A, 1990, HEALTH POLICY, V16, P199